Vermont Immunobiology / Infectious Diseases Center

佛蒙特州免疫生物学/传染病中心

基本信息

批准号：
10006835
负责人：
Ralph C Budd
金额：
$ 116.48万
依托单位：
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-05 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10006835
关键词：
Area Atmosphere Avian Influenza Award Bacterial Infections Bangladesh Basic Science Bioinformatics Categories Centers of Research Excellence Child Clinical Clinical Trials Commercial Sectors Communicable Diseases Core Facility Dengue Dengue Vaccine Development Diagnostic Disease Outbreaks Ebola Educational workshop Emerging Communicable Diseases Environment Faculty Fostering Foundations Funding Genome Grant Health Home environment Human poliovirus Immune response Immunobiology Immunology Infection Infrastructure Investigation Joints Laboratories Legal patent Mass Spectrum Analysis Massive Parallel Sequencing Measles virus Mentors Methodology Microbiology Middle East Respiratory Syndrome National Institute of Allergy and Infectious Disease Paper Parasitic infection Pathogenesis Phase Pilot Projects Poliomyelitis Post-Translational Protein Processing Program Research Project Grants Proteomics Public Health Publications Publishing Research Research Personnel Research Project Grants Scientific Advances and Accomplishments Scientist Series Structure Talents Technology Therapeutic Time Training United States National Institutes of Health Universities Vermont Virulent Virus Diseases Wing Writing base biosafety level 3 facility college experience innovation instrumentation interest mass spectrometer metabolomics microbial mid-career faculty multidisciplinary next generation sequencing novel vaccines pathogen programs public health relevance response senior faculty skills sound tenure track vaccine evaluation working group

项目摘要

The Vermont Center for Immunology and Infectious Diseases (VCIID) COBRE is about to enter its 10th year. During this period, VCIID has grown from 9 founding faculty to 25 and produced 416 publications and $92 million in grant support and 14 patents. Twelve junior faculty were supported with COBRE funding during Phases I and II (10 tenure track and 5 have already achieved tenure) and they published 118 papers and garnered $13.2 million in funding (including 4 new R01 grants) while still junior faculty. Junior faculty also received several awards, including a Pew Scholars Award. Institutional support from the University of Vermont (UVM) during this period was also a robust $2.9 million. The VCIID has demonstrated its development into a mature collaborative center by a variety of metrics. Its faculty has received a P01 Program Project Grant and a T32 Training Grant, both of which were renewed. One of the former junior faculties has established the Vaccine Testing Center (VTC) as a clinical trials wing of the VCIID. It is currently conducting trials for a new dengue virus vaccine with NIAID funding, and examining why undernourished children in Bangladesh do not respond to polio virus with funding from the Bill & Melinda Gates Foundation. To date VTC has received $18.5 million in funding. To fulfill a growing need for a BSL3 facility for VCIID faculty, we were economically innovative by leveraging a COBRE ARRA supplement to support a collaborative venture with the Vermont Department of Health in which UVM donated land on the UVM campus to build a new Department of Health laboratory containing a large joint BSL3/ABSL3 facility paid and maintained by the Department of Health. This will also foster interactions between VCIID investigators and Department of Health staff, and hence move us into the realm of public health. As we approach Phase III we will motivate VCIID faculty through a Pilot project Program to collaborate on common research themes to prepare for new collaborative R01, P01 and U-19 applications, as well as to move their research in a translational and entrepreneurial direction with our new SPARK-VT Program. Our cores in Genome Technologies/Bioinformatics and Mass Spectrometry/Proteomics have both upgraded instrumentation during Phase II and diversified their user base. Combined with institutional commitments for five years beyond the end of Phase III, we feel we have achieved the metrics to begin a successful Phase III COBRE period.

佛蒙特州免疫和传染病中心（VCIID）COBRE即将进入其第10年。在此期间，VCIID已从9个成立教师增长到25个，并生产了416个出版物和9200万美元的赠款支持和14项专利。在第一阶段和II阶段（10个任期和5个任期）期间，十二名初级教师得到了鞋垫资金的支持，他们发表了118篇论文，并获得了1320万美元的资金（包括4个新的R01赠款），而仍然是初级教职员工。初级教师还获得了几个奖项，包括皮尤学者奖。在此期间，佛蒙特大学（UVM）的机构支持也是290万美元。 VCIID已通过各种指标证明了其发展成一个成熟的协作中心。它的教职员工已获得P01计划项目赠款和T32培训补助金，这两者均已续签。前初级学院之一已将疫苗测试中心（VTC）建立为VCIID的临床试验机翼。目前，它正在对NIAID资助的新登革热病毒疫苗进行试验，并研究了为什么孟加拉国营养不良的儿童不通过Bill＆Melinda Gates Foundation的资金来应对脊髓灰质炎病毒。迄今为止，VTC已获得1,850万美元的资金。为了满足对VCIID教师BSL3设施的日益增长的需求，我们通过利用COBRE ARRA补充剂来支持与佛蒙特州卫生部的合作企业，在经济上是创新的，UVM捐赠了UVM校园的土地，以建立一个新的卫生部实验室，其中包含卫生部和维持卫生部支付和维护的大型BSL3/ABSL3设施。这还将促进VCIID调查人员与卫生部门工作人员之间的互动，从而使我们进入公共卫生领域。当我们接近第三阶段时，我们将通过一项试点项目计划激励VCIID教职员工，以合作以共同的研究主题进行合作，为新的合作R01，P01和U-19应用程序做准备，并与我们的新Spark-VT计划一起以转化和企业家的方向进行转化和企业家方向。我们的基因组技术/生物信息学和质谱/蛋白质组学的核心在II期期间升级了仪器，并使其用户群多样化。结合了第三阶段结束之前五年的机构承诺，我们认为我们已经实现了成功的III期cobre时期的指标。